OncoMatch/Clinical Trials/NCT02392572
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Is NCT02392572 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Akt/ERK Inhibitor ONC201 and Venetoclax for recurrent acute lymphoblastic leukemia.
Treatment: Akt/ERK Inhibitor ONC201 · Venetoclax — This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). ONC201 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any standard or investigational treatment for hematologic malignancy
Exception: at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents since last treatment
Patients receiving any other standard or investigational treatment for their hematologic malignancy within past 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents
Lab requirements
Kidney function
Serum creatinine < 2.0 mg/dl
Liver function
Total bilirubin <= 1.5 x ULN unless considered due to Gilbert's syndrome; ALT or AST <= 3 x ULN unless considered due to organ leukemic involvement
Serum creatinine < 2.0 mg/dl; Total bilirubin <= 1.5 x ULN unless considered due to Gilbert's syndrome; ALT or AST <= 3 x ULN unless considered due to organ leukemic involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify